Mach7 Technologies Ltd (ASX: M7T) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Mach7 Technologies Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Mach7 Technologies Ltd (ASX: M7T)
Latest News
Small Cap Shares
3 small cap ASX shares to buy for massive returns
Small Cap Shares
3 small cap ASX shares to buy for very big returns
52-Week Lows
Why I think this ASX penny stock is a bargain at its 52-week low
Earnings Results
Can this ASX healthcare stock, down 22% in a year, turn the tide after FY24 results?
Small Cap Shares
3 small cap ASX stocks that could rise 40% to 100%+
Small Cap Shares
Morgans rates these ASX small-cap shares as best buys
Small Cap Shares
3 ASX penny stocks I don't think will be below 80 cents much longer
Healthcare Shares
Why this little ASX healthtech share is charging 7% to a 52-week high on Friday
Small Cap Shares
Broker says these small cap ASX shares offer big returns potential
Best Shares
Top ASX shares to buy in January 2023
Healthcare Shares
Mach7 signs $17 million contract – share price jumps 20% at open
Share Gainers
Why AGL, Invictus Energy, Maas, and Mach7 shares are pushing higher today
Frequently Asked Questions
-
No, this ASX small-cap share has never paid dividends.
-
Mach7 Technologies has been listed on the ASX since 30 November 2005.
M7T ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
---|---|---|---|---|---|
YesNo |
About Mach7 Technologies Ltd
Mach7 Technologies Ltd (ASX: M7T) is a medical imaging systems provider that develops innovative image management and viewing solutions for healthcare organisations. Its systems create a clear and complete view of the patient to inform diagnosis, reduce care delivery delays and costs, and improve patient outcomes. This allows healthcare enterprises to identify, connect, and share diagnostic image and patient care intelligence.
Mach7 has more than 150 customers in 15 countries and derives a majority of its revenue from North America.
M7T Share Price History Data provided by Morningstar.
Date | Close | Change | % Change | Volume | Open | High | Low |
---|---|---|---|---|---|---|---|
20 Dec 2024 | $0.33 | $0.01 | 3.08% | 1,150,798 | $0.33 | $0.34 | $0.33 |
19 Dec 2024 | $0.33 | $-0.01 | -3.03% | 1,388,223 | $0.34 | $0.34 | $0.33 |
18 Dec 2024 | $0.33 | $0.00 | 0.00% | 534,016 | $0.33 | $0.34 | $0.33 |
17 Dec 2024 | $0.33 | $0.01 | 3.13% | 1,156,629 | $0.32 | $0.34 | $0.32 |
16 Dec 2024 | $0.32 | $-0.01 | -3.08% | 219,358 | $0.33 | $0.33 | $0.32 |
13 Dec 2024 | $0.33 | $-0.01 | -3.03% | 456,864 | $0.33 | $0.33 | $0.31 |
12 Dec 2024 | $0.33 | $-0.01 | -2.94% | 314,096 | $0.34 | $0.34 | $0.33 |
11 Dec 2024 | $0.34 | $0.00 | 0.00% | 310,916 | $0.36 | $0.36 | $0.33 |
10 Dec 2024 | $0.34 | $-0.02 | -5.63% | 905,798 | $0.36 | $0.36 | $0.34 |
09 Dec 2024 | $0.36 | $-0.01 | -2.78% | 452,766 | $0.36 | $0.37 | $0.36 |
06 Dec 2024 | $0.36 | $-0.01 | -2.74% | 435,134 | $0.37 | $0.37 | $0.36 |
05 Dec 2024 | $0.37 | $0.01 | 2.78% | 260,883 | $0.36 | $0.37 | $0.36 |
04 Dec 2024 | $0.36 | $0.00 | 0.00% | 401,797 | $0.37 | $0.37 | $0.36 |
03 Dec 2024 | $0.36 | $-0.01 | -2.70% | 272,426 | $0.37 | $0.37 | $0.36 |
02 Dec 2024 | $0.37 | $0.01 | 2.74% | 391,883 | $0.37 | $0.38 | $0.37 |
29 Nov 2024 | $0.37 | $-0.02 | -5.26% | 638,360 | $0.38 | $0.38 | $0.36 |
28 Nov 2024 | $0.38 | $0.02 | 5.56% | 1,123,208 | $0.37 | $0.39 | $0.36 |
27 Nov 2024 | $0.36 | $-0.01 | -2.74% | 369,683 | $0.37 | $0.37 | $0.36 |
26 Nov 2024 | $0.37 | $0.00 | 0.00% | 249,381 | $0.37 | $0.37 | $0.37 |
25 Nov 2024 | $0.37 | $0.02 | 5.71% | 581,961 | $0.35 | $0.37 | $0.35 |
22 Nov 2024 | $0.35 | $-0.01 | -2.82% | 134,841 | $0.36 | $0.36 | $0.35 |
21 Nov 2024 | $0.36 | $-0.01 | -2.78% | 461,295 | $0.36 | $0.36 | $0.35 |
20 Nov 2024 | $0.36 | $0.00 | 0.00% | 75,704 | $0.36 | $0.36 | $0.36 |
Director Transactions Data provided by Morningstar.
Date | Director | Type | Amount | Value | Notes |
---|---|---|---|---|---|
12 Dec 2024 | Mike Lampron | Buy | 46,000 | $16,330 |
On-market trade.
|
09 Dec 2024 | Mike Lampron | Issued | 800,000 | $284,000 |
Issue of securities. 2,223,000 Performance Rights
|
05 Dec 2024 | Robert Bazzani | Buy | 54,700 | $19,998 |
On-market trade.
|
03 Dec 2024 | Robert Bazzani | Buy | 27,395 | $9,999 |
On-market trade.
|
02 Dec 2024 | Robert Bazzani | Buy | 53,333 | $19,962 |
On-market trade.
|
28 Nov 2024 | Rebecca Thompson | Buy | 400,000 | $148,000 |
On-market trade.
|
19 Nov 2024 | Eliot Siegel | Expiry | 25,000 | $9,000 |
Options expired.
|
19 Nov 2024 | Mike Lampron | Expiry | 750,000 | $270,000 |
Options expired.
|
19 Nov 2024 | Robert Bazzani | Expiry | 225,000 | $81,000 |
Options expired.
|
30 Sep 2024 | Mike Lampron | Expiry | 402,185 | $223,212 |
As advised by the company. 1,423,000 Performance Rights, lapsed
|
21 May 2024 | Robert Bazzani | Buy | 29,400 | $19,944 |
On-market trade.
|
Directors & Management Data provided by Morningstar.
Name | Title | Start Date | Profile |
---|---|---|---|
Dr Eliot L Siegel | Non-Executive Director | Aug 2018 |
Dr. Siegel is a thought leader in the world of radiology and imaging informatics and artificial intelligence applications in medicine. He is currently Professor at the University of Maryland School of Medicine, Department of Diagnostic Radiology, and also works for the Veterans Affairs Maryland Healthcare System, in Baltimore, MD as well as adjunct professor of computer science and biomedical engineering at the undergraduate campuses of the University of Maryland. He is a pioneer and co-founder of United Theranostics, a company created to bring state-of-the-art radiopharmaceuticals to patients for cancer therapy. Under his guidance, the VA Maryland Healthcare System became the first filmless healthcare enterprise in the World. He has written over 300 articles and book chapters about PACS (Picture Archiving and Communication Systems) and digital imaging, and has edited books on the topic, including Filmless Radiology and Security Issues in the Digital Medical Enterprise. He has given more than 1,000 presentations throughout the world on a range of topics involving the use of computers in medicine and artificial intelligence. Dr. Siegel was symposium chairman for the Society of Photo-optical and Industrial Engineers (SPIE) Medical Imaging Meeting for three years and has been honored as a fellow in that organisation as well as the American College of Radiology and the Society of Imaging Informatics in Medicine. He is also a Board member of Carestream Health and serves on advisory boards in medical imaging. He us Risk Management Committee member. Former directorships (last 3 years): Carestream Health.
|
Mr Mike Lampron | Chief Operating OfficerChief Executive OfficerManaging Director | Mar 2019 |
Mr. Lampron is the CEO of Mach7 Technologies. With over 20 years of experience in business and operational management for Healthcare IT companies, Michael brings experience ranging from private start-up organizations as well as established companies such as IBM and GE. Michael was previously the Chief Executive Officer for a National Teleradiology Company and has ability to drive results through a combination of astute analysis, innovative execution and cross-functional teamwork. Michael is responsible for our customers' success while driving excellence throughout Mach7. Former directorships (last 3 years): Watchtower Consultants, LLC.
|
Mr Robert John Bazzani | Non-Executive Director | Jan 2020 |
Mr Bazzani spent 20 years with the global consulting firm KPMG, where he rose to the top and served as Chairman of KPMG Victoria, National Managing Partner for KPMG Australia's Enterprise Division and National Managing Partner for KPMG's M&A Division. Whilst in these roles, Rob was a member of KPMG's National Executive Committee (NEC), which oversees and is responsible for the Firm's turnover, strategic decision making, profitability and operations. Rob has a track record of leading and growing businesses. He has played a role in advising clients (public, private, and global subsidiaries) on commercial matters, public transitions, corporate governance, investment banking and law, M&A and has engaged with Government and Regulators. With experience in corporate advisory, Rob has deep commercial and industry knowledge across financial services, asset and wealth management, technology, property, insurances and consumer & industrial markets. He is Risk Management Committee member.
|
Mr Peter Gundy | Non-Executive Director | Nov 2023 |
--
|
Ms Rebecca Thompson | Non-Executive Director | Nov 2023 |
Ms Thompson has more than 25 years of financial markets experience gained at global investment banks, listed companies and a fintech start-up. Rebecca's executive career included seven years at J.P, Morgan as the Head of Corporate Broking followed by a role at KPMG Australia as the Head of Capital Advisory and most recently Head of Investor Relations for CSR Limited (ASX:CSR). Rebecca has a skillset across equities, property, and foreign exchange with experience in the real estate, building materials, healthcare, resources and software industries. Stakeholder relations, communications, sustainability and financial analysis are core competencies Other current directorships: Independent Community Living Australia (ICLA), Non-Executive Director; MarketMeter, Non-Executive Director. He is risk Management Committee Chair.
|
Mr Tony Panther | Company Secretary | Feb 2023 |
-
|
Tony Panther | Company Secretary |
-
|
Top Shareholders Data provided by Morningstar.
Name | Shares | Capital |
---|---|---|
National Nominees Limited | 32,877,317 | 13.63% |
Sandhurst Trustees Ltd (Jmfg Consol A/C) | 31,114,880 | 12.90% |
J P Morgan Nominees Australia Pty Limited | 27,668,371 | 11.47% |
HSBC Custody Nominees (Australia) Limited | 22,684,257 | 9.40% |
Citicorp Nominees Pty Limited | 9,721,484 | 4.03% |
Ubs Nominees Pty Ltd | 9,233,020 | 3.83% |
Pt Dwi Satrya Utama | 4,392,959 | 1.82% |
Padmalwar Prakash | 3,569,921 | 1.48% |
Chew & Partners (Import & Export) Pte Ltd | 2,900,074 | 1.20% |
Perco Group Pty Ltd (F S P A/C) | 2,840,000 | 1.18% |
Microequities Asset Management Pty Ltd (Microeqts Nanocap No 11 A/C) | 2,823,641 | 1.17% |
BNP Paribas Nominees Pty Ltd (Ib Au Noms Retailclient) | 1,718,707 | 0.71% |
Supernatural Super Pty Ltd (The Supernatural Super A/C) | 1,715,500 | 0.71% |
Albert Liong Pak-Fai | 1,544,189 | 0.64% |
Bpnt Pty Ltd (Heaney Family Super Fund A/C) | 1,539,283 | 0.64% |
Ty Webb Pty Ltd (Ty Webb A/C) | 1,339,444 | 0.56% |
BNP Paribas Noms Pty Ltd | 1,303,411 | 0.54% |
Mrs Jennifer Lee Pilcher | 1,294,856 | 0.54% |
62 Darlinghurst Road Pty Ltd | 1,000,000 | 0.41% |
HSBC Custody Nominees (Australia) Limited (Gsco Customers A/C) | 964,287 | 0.40% |